WHO and ECDC Warn Antibiotic Resistance Is Undermining Treatment Options Across Europe

WHO and ECDC Warn Antibiotic Resistance Is Undermining Treatment Options Across Europe

A laboratory culture dish being examined during microbiology research

Health authorities have issued a renewed warning about antibiotic resistance across Europe after new surveillance findings showed that important treatments are failing against serious hospital infections in many countries.

A joint analysis released by the World Health Organization's Regional Office for Europe and the European Centre for Disease Prevention and Control on Wednesday, 18 November, found that in about half of the countries reporting data, at least half of the tested samples of two important hospital bacteria were resistant to key antibiotics.

The findings were published as Europe marked European Antibiotic Awareness Day, placing the issue back in focus for health services, policymakers and patients.

What the new European data show

The analysis examined Klebsiella pneumoniae and Acinetobacter, bacteria that can cause serious infections, including infections affecting the bloodstream. Among 43 countries reporting data for Klebsiella pneumoniae, 21 recorded resistance to third-generation cephalosporins in at least half of the samples tested.

The findings also show that in 10 of those 43 countries, at least half of the tested Klebsiella pneumoniae samples were resistant to carbapenems. These medicines are broad-spectrum antibiotics used for serious infections when other treatment options may not be suitable. For Acinetobacter, 21 of 38 reporting countries recorded resistance to key antibiotics in at least half of the samples.

These figures describe laboratory results from reported samples. They do not mean that half of all hospital patients in those countries have resistant infections, and the reporting coverage differs between countries.

Why treatment options are becoming harder to protect

When commonly used antibiotics stop working reliably, clinicians may need to turn to stronger medicines. If resistance also develops against those drugs, the number of available treatment options can become very limited.

The ECDC's separate 18 November assessment highlighted a worsening situation involving carbapenem-resistant Enterobacterales. It reported that bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae in the EU and European Economic Area had increased by an estimated 72% between 2019 and 2025.

Prevention and responsible use matter

WHO and ECDC are calling for better infection prevention in hospitals, stronger laboratory surveillance, properly funded national action plans and responsible use of antibiotics. Patients should not start, stop or change prescribed medicines without advice from an appropriate healthcare professional.

Antibiotics do not treat viral illnesses such as ordinary colds and flu. Using them when they are not needed can contribute to the wider problem of antimicrobial resistance.

A challenge for health systems

The new findings do not mean Europe has lost the ability to treat bacterial infections. They do show that progress is uneven and that several important targets remain difficult to achieve.

For patients, reliable testing and effective infection control can help ensure that treatment decisions are based on better information. For governments, the challenge is to turn national strategies into funded action. The message from Europe's health authorities is clear: preserving antibiotics requires sustained work from hospitals, laboratories, policymakers and the public.

Sources: WHO/Europe: Resistance to key antibiotics across the Region; ECDC: Carbapenem-resistant Enterobacterales assessment.

Image credit: Edward Jenner / Pexels. Illustrative stock photograph.

 

إرسال تعليق

أحدث أقدم

Homepage In-Feed Ad Slot

Sidebar Ad Slot